Latest news with #Hayward
West Australian
7 hours ago
- Entertainment
- West Australian
Books for Little Bookaburras ambassador & local WA author Renae Haywarth brings stories to Geraldton kindies
Young Geraldton students have been treated to a new reading initiative that delivers important storytelling, children's books and joy to regional kindergarteners. As part of the regional celebration of the Fremantle Press 2025 Books for Little Bookaburras program, Bookaburras ambassador and WA author Renae Hayward will visit three kindies across regional WA, starting with Beachlands Kindilink which she visited on Wednesday. Mini libraries — sets of books especially curated for young readers — are given to each child, before an interactive storytime session is held by Hayward for the excited students. The Little Bookaburras initiative, supported by a growing number of sponsors and creatives, will reach more than 4500 children across WA, ensuring access to books no matter where they live. Hayward said: 'Books are so important for children aged 0-3 years. Books expose kids to new words and concepts, and can even help build empathy. 'I'm so thrilled to be an ambassador for the Bookaburras program, which puts books by WA creators into the hands of kids who might not have that many books of their own, if any. 'It was such a joy to hand out the Bookaburras book packs at Beachlands Primary School KindiLinks. The kids immediately started reading their new books with their grown-ups, which is what we love to see.' Fremantle Press CEO Alex Allan said the initiative was having a real impact on young regional WA readers. 'Last year over a third of our participants were based in regional areas,' he said. 'Some 200 of the total number of children had no other access to books, and others didn't have homes to take them to at all. 'The program is providing a much-needed permanent resource for families — a set of books for the kids to treasure and a valuable resource for carers to use to build literacy and a life-long love of stories.' The program's mini-libraries feature stories by local authors and First Nations storytellers, with titles that reflect the richness of Australian voices. Each child recieves books such as Say Hello or Say Goodbye by Hayward and fellow author Rebecca Mills, along with Indigenous stories like Crow and the Water Hole by Ambelin Kwaymullina or In Your Dreams by Sally Morgan and Bronwyn Bancroft. In a touching show of support, all creators of the 2025 books have donated their royalties back to the program, helping it grow and reach even more children.
The Citizen
11 hours ago
- General
- The Citizen
How to enjoy school more
'Children are calmer when they know what to expect' Twelve years or more of learning, of school, of uniforms and routine sound like torture in retrospect. We've all been through it and survived, and our kids are in the system. But going to school does not have to feel like a sausage machine exercise that's got stress and dread written all over it. It does take a village to raise a child, and in the twenty-first century, that village looks to teachers to complete the circle. Educator Richard Hayward's new book Give Quality Kids Quality School Days is a kind of Hitch Hiker's Guide to all of this. It's for teachers and parents, and Hayward said his sole objective for authoring the work was to help turn twelve years of classroom into a dozen times three six five of skipping, smiling, into them, not dreading the process. 'I've seen kids who love school, and I've seen others who struggle,' he said. 'The book is about what makes the difference, and how anyone who cares for a child can help.' It is not just a guide for teachers. This is for parents, uncles, neighbours, coaches and anyone else who wants a child to have a better day. It is a practical approach. From choosing the right school in the first place to helping a child make sense of their day when it all goes pear-shaped. Happiness is linked to emotional intelligence Hayward said that a child's happiness at school is often linked to emotional intelligence, and that starts at home. 'Happy children are often the ones who know how to treat others. They are kind, they have support systems, and they've learnt resilience,' he said. Also Read: Budgeting for baby: Here are the most useless items parents buy Despite this, not every day is going to be a joyful celebration. 'There will be days when things fall apart. Someone gets bullied. A teacher shouts. A child fails a test or does not make the team. The book gives real ideas on how to handle that and help the child find their footing again.' There's also something quite important that he called learned helplessness, where children stop trying because they think they are not good enough. 'Children need to be shown how to hang in there. How to get through disappointment. And how to discover what they're good at,' he said. It's a strong theme throughout the book because Hayward said his view is that everyone is gifted. You just must look in the right places. 'We used to think a smart kid was one who could do maths and read well,' Hayward said. 'But that is narrow. There are many forms of intelligence. A child might struggle in class but shine on the sports field. That should be celebrated too.' The work is filled with anecdotes from his days as an educator. One of his favourites tells of a boy named who battled with traditional subjects but was a genius at soccer. 'He could read the game, anticipate plays, and execute with precision. That's intelligence. Just not the kind you measure with a test.' The importance of routine and rhythm He shared that for children to enjoy school more, the adults around them should also focus on routine and rhythm. 'Children are calmer when they know what to expect,' he said. 'A simple routine like having dinner at a regular time, getting enough sleep, packing their bag the night before. It all helps reduce anxiety.' Kindness, he added, should never be underestimated. 'I tell the story of a young girl in the book,' Hayward said. 'There's a boy in the class who always forgets his pen. The teacher asks everyone for a spare, but before he can say a word, the young lady already has her hand up. She's holding out a pen. No judgement. Just kindness.' The way a school handles recognition also matters, said Hayward. He described a school assembly where clapping was kept consistent, no matter the award. 'Whether it was for art, music, sport or academics, the applause was the same. That teaches children that every contribution matters. Not just the ones that come with a trophy.' Hayward also suggested that restorative discipline rather than punitive approaches can make a substantial difference. 'You can't run a school like a game reserve, with everyone doing what they like,' he said. 'But you also don't need humiliation or fear. When children step out of line, we help them see why it was wrong and what they can do to fix it. That's discipline with dignity.' Values start at the top Values start at the top. 'If school leadership gets their values right, it filters into everything,' he said. 'From the staff room to the classroom, it sets the tone. You can have order and still have joy. You can have discipline and still have laughter.' Give Quality Kids Quality School Days, said Hayward, is not a silver bullet. Instead, it is full of useful tools, anecdotes and small suggestions that could make a big difference in a child's life. 'Because every child deserves more happy school days than hard ones. And sometimes, it just takes one adult who cares to make that happen.' Now Read: It's lekker, messy creativity and art
Yahoo
a day ago
- Business
- Yahoo
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line ccRCC patients, both of which will begin shortly Arcus will host a conference call to discuss these data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025 HAYWARD, Calif., June 01, 2025--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. "I was very encouraged to see that nearly half of patients had a confirmed response to the casdatifan plus cabozantinib combination despite short follow-up," said Toni K. Choueiri, M.D., director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber, the Jerome and Nancy Kohlberg Chair and professor of medicine at Harvard Medical School, and lead investigator of ARC-20. "Casdatifan plus cabozantinib was well tolerated, and the safety profile was consistent with that of either agent alone, supporting their potential as a combination therapy. I look forward to enrolling patients into the PEAK-1 trial as soon as it is open." "The initial data for casdatifan plus cabozantinib in the ARC-20 study have already exceeded the historic benchmarks for either agent alone, as well as that of another HIF-2a inhibitor plus cabozantinib in the same second-line setting," said Terry Rosen, Ph.D., chief executive officer of Arcus. "These data serve as the proof of concept for PEAK-1, which will be initiated in the coming weeks and is designed to generate evidence to change the standard of care for people who have progressed on prior immunotherapy treatment." ARC-20 is a Phase 1/1b dose-escalation and expansion study that includes a cohort evaluating once-daily 100mg of casdatifan plus 60mg of cabozantinib in patients with ccRCC who had progressed on prior immunotherapy. At the time of the data cutoff (DCO, March 14, 2025), 42 participants were evaluable for safety, and 24 reached at least 12 weeks of follow-up and were evaluable for efficacy. Among the safety-evaluable population (N=42), most participants (79%) had an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factor of intermediate or poor. Nearly half (46%) of the efficacy-evaluable population (N=24) achieved a confirmed response per RECIST 1.1, and only one patient had primary progressive disease. The vast majority of the efficacy-evaluable population remains on treatment. In the safety-evaluable population, no unexpected safety risks were identified at the time of DCO, and casdatifan plus cabozantinib had an acceptable safety profile with no meaningful overlapping toxicity for the two drugs. Only two patients discontinued any drug, and no patients discontinued treatment with both drugs. The incidence of treatment-emergent adverse events (TEAEs) with casdatifan, particularly anemia and hypoxia, was similar to TEAEs observed with casdatifan monotherapy, and there were no casdatifan-related Grade 4 or 5 adverse events. The incidence of TEAEs associated with each drug was consistent with what is expected for each drug alone. A summary of the efficacy and safety results is below. Efficacy-Evaluablea casdatifan 100mg QD + cabozantinib 60mg QD (n=24) Median Follow-Up 5.3 months Confirmed ORR (cORR) per RECIST v1.1 [95% CI] 46% (11)b [26,67] Best Overall Response: Complete Response 4% (1) Partial Response 42% (10)b Stable Disease 50% (12) Progressive Disease 4% (1) CI: confidence interval; QD: daily a All eligible patients who received any study treatment and reached a minimum of 12 weeks follow-up or discontinued due to progression or death. b Inclusive of one patient who had partial response confirmation after March 14, 2025. Safetya casdatifan 100mg QD + cabozantinib 60mg QD (n=42) casdatifan cabozantinib Patients with any Treatment-Related Grade ≥3 AEb Anemia 24% (10) 14% (6) Hyponatremia 0 7% (3) Hypoxia 7% (3) 0 Hypertension 0 5% (2) Neutrophil count decrease 2% (1) 5% (2) Patients with any AE leading to dose reductionb Fatigue 2% (1) 12% (5) Anemia 10% (4) 2% (1) Hypoxia 10% (4) 0 Palmar-plantar erythrodysesthesia 0 5% (2) Stomatitis 0 5% (2) AE: adverse event a Safety population included patients who received any amount of study drug and had at least one month of safety follow-up at the data cutoff date. b Treatment-emergent adverse events (grade 3 or higher) related to casdatifan, cabozantinib, or any study drug reported in ≥3% of patients in any treatment arm. Arcus is pursuing a broad development program in both the immuno-oncology (IO)-naive and post-IO settings with differentiated combinations to maximize the opportunity for casdatifan in ccRCC. These studies include: Arcus's planned Phase 3 study, PEAK-1, which will evaluate casdatifan plus cabozantinib versus cabozantinib monotherapy as a first- or second-line treatment in patients with metastatic ccRCC who have previously received anti-PD-1/PD-L1 therapy. The primary endpoint will be PFS with a key secondary endpoint of overall survival. eVOLVE-RCC02, a Phase 1b/3 study sponsored by AstraZeneca, which will evaluate casdatifan plus volrustomig, an investigational anti-PD-1/CTLA-4 bispecific antibody, as first-line treatment for participants with ccRCC. ARC-20, which includes three cohorts evaluating casdatifan in earlier-line settings, including casdatifan plus zimberelimab in first-line ccRCC, casdatifan monotherapy in favorable risk ccRCC, and casdatifan monotherapy in immunotherapy-experienced, TKI-naive settings. Investors may dial in to the conference call at +1 404 975 4839 (local) or +1 833 470 1428 (toll-free) using Conference ID: 446724 on Monday, June 2, 2025, at 5:00 AM PT / 7:00 AM CT. Participants may also register for the call online using the following link: To access the live webcast and accompanying slide presentation, please visit the "Investors & Media" section of the Arcus Biosciences website at A replay will be available following the live event. About Casdatifan (AB521) Casdatifan is a small-molecule inhibitor of HIF-2a, a transcription factor responsible for activating multiple tumor growth pathways in hypoxic and pseudo-hypoxic tumor environments. By selectively binding HIF-2a, casdatifan is designed to shut down hypoxic oncogenesis and key oncogenic pathways, which leads to cancer cell death. Clear cell renal cell carcinoma is almost universally associated with HIF-2a dysregulation. Casdatifan is currently being evaluated in ARC-20, a Phase 1/1b study in renal cell carcinoma. Casdatifan is an investigational molecule. Approval from any regulatory authority for its use has not been received, and its safety and efficacy have not been established. About RCC According to the American Cancer Society, kidney cancer is among the top 10 most commonly diagnosed forms of cancer among both men and women in the U.S., and an estimated 80,980 Americans will be diagnosed with kidney cancer in 2025. Clear cell RCC is the most common type of kidney cancer in adults. If detected in its early stages, the five-year survival rate for RCC is high; for patients with advanced or late-stage metastatic RCC, however, the five-year survival rate is only 18%. In 2022, approximately 32,200 patients with advanced kidney cancer required systemic therapy in the U.S., with over 20,000 patients receiving first-line treatment. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences' clinical and preclinical programs, please visit Forward Looking Statements This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the statements in Dr. Choueiri's and Dr. Rosen's quotes and statements regarding: the potency, efficacy or safety of casdatifan, including its potential for a best-in-class profile and potential as a combination therapy; and Arcus's development plans for the casdatifan program, including expected timing and design for new studies and cohorts and plans for generating data to support initiation of future studies. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus's actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to risks associated with: interim data not being replicated in future studies evaluating the same investigational molecules or regimen; the unexpected emergence of adverse events or other undesirable side effects with casdatifan; risks associated with manufacturing or supplying product for such clinical trials; uncertainties in timelines associated with the conduct of clinical studies and with respect to the regulatory application process; difficulties associated with the management of the collaboration activities with our strategic partners or expanded clinical programs; changes in the competitive landscape for Arcus's programs; and the inherent uncertainty associated with pharmaceutical product development and clinical trials. Risks and uncertainties facing Arcus are described more fully in the "Risk Factors" section of Arcus's most recent periodic report filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release except to the extent required by law. The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners. View source version on Contacts Investor Inquiries: Pia EavesVP of Investor Relations & Strategy(617) 459-2006peaves@ Media Inquiries: Holli KolkeyVP of Corporate Affairs(650) 922-1269hkolkey@ Maryam BassiriAD, Corporate Communications(510) 406-8520mbassiri@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Hayward Holdings to Participate in the William Blair 45th Annual Growth Stock Conference
CHARLOTTE, N.C., May 30, 2025--(BUSINESS WIRE)--Hayward Holdings, Inc. (NYSE: HAYW) ("Hayward" or the "Company"), a global designer, manufacturer, and marketer of a broad portfolio of pool equipment and outdoor living technology, announced today that it will be participating in the William Blair 45th Annual Growth Stock Conference in Chicago, Illinois, on Thursday, June 5, 2025. Management is scheduled to present on Thursday, June 5, at 10:00 a.m. CT (11:00 a.m. ET). A link to the live webcast of the presentation and additional Company information can be found on the investor relations section of Hayward's website at About Hayward Holdings, Inc. Hayward Holdings, Inc. (NYSE: HAYW) is a leading global designer and manufacturer of pool and outdoor living technology. With a mission to deliver exceptional products, outstanding service and innovative solutions to transform the experience of water, Hayward offers a full line of energy-efficient and sustainable residential and commercial pool equipment including pumps, filters, heaters, cleaners, sanitizers, LED lighting, and water features all digitally connected through Hayward's intuitive IoT-enabled SmartPad™. View source version on Contacts Investor Relations: Kevin Media Relations: Misty Zelentmzelent@ Sign in to access your portfolio
Business Wire
3 days ago
- Business
- Business Wire
Hayward Holdings to Participate in the William Blair 45 th Annual Growth Stock Conference
CHARLOTTE, N.C.--(BUSINESS WIRE)--Hayward Holdings, Inc. (NYSE: HAYW) ('Hayward' or the 'Company'), a global designer, manufacturer, and marketer of a broad portfolio of pool equipment and outdoor living technology, announced today that it will be participating in the William Blair 45 th Annual Growth Stock Conference in Chicago, Illinois, on Thursday, June 5, 2025. Management is scheduled to present on Thursday, June 5, at 10:00 a.m. CT (11:00 a.m. ET). A link to the live webcast of the presentation and additional Company information can be found on the investor relations section of Hayward's website at About Hayward Holdings, Inc. Hayward Holdings, Inc. (NYSE: HAYW) is a leading global designer and manufacturer of pool and outdoor living technology. With a mission to deliver exceptional products, outstanding service and innovative solutions to transform the experience of water, Hayward offers a full line of energy-efficient and sustainable residential and commercial pool equipment including pumps, filters, heaters, cleaners, sanitizers, LED lighting, and water features all digitally connected through Hayward's intuitive IoT-enabled SmartPad™.
